NOVAVAX EXEC SAYS TOO EARLY TO SAY IF OMICRON-SPEFCIFIC VACCINE IS THE RIGHT APPROACH OR IF ORIGINAL COVID-19 VACCINE GENERATES A SUFFICIENTLY BROAD PROTECTIVE RESPONSE TO USE AS A BOOST- JPM CONF
Stock Market News
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
16.44 USD | +8.73% | +38.85% | 2.12B | ||
- Stock Market
- Stock Market News
- Economy
- Novavax Exec Says Too Early To Say If Omicron-Spefcific Vaccine Is The Right Approach Or If Original Covid-19 Vaccine Generates A Sufficiently Broad Protective Response To Use As A Boost- Jpm Conf